Attorney Advertising. Mylan N.V. (NASDAQ: MYL) may be significantly overcharging patients for its EpiPen allergy shot. Since Mylan acquired the drug in 2007, the price has increased six-fold, from $100 to $600 for two doses. Yet Mylan pays only $34.50 per pen.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161006006550/en/

Since Mylan acquired the drug in 2007, the price has increased six-fold, from $100 to $600 for two doses. Yet Mylan pays only $34.50 per pen. (Photo: Business Wire)

The EpiPen is a small device that automatically injects a dose of the drug epinephrine into the thigh to counter life-threatening reactions to allergens such as peanuts, shellfish and bee stings. According to National Food Allergy Guidelines, a delay in administering epinephrine can be life-threatening.

Mylan claims the price increase can be explained by more than $1 billion it has invested to improve the EpiPen. In 2009 Mylan launched an upgraded version of the EpiPen; however, recent independent studies show there is little change to the design of the pen. PA Consulting Group, a UK-based technology consulting firm, found that “it’s the same core device that’s been used for some time.” The firm estimates the redesign may have only cost Mylan several million dollars. In 2015, the EpiPen brought in over $1 billion in sales for the company.

If you or someone you know has purchased an EpiPen since 2007, please contact attorneys Michael Meredith or Gretchen Freeman Cappio. Call 800-776-6044 or email consumer@kellerrohrback.com.

Keller Rohrback L.L.P. has decades of experience helping consumers and insureds fight back against fraud and abuse. Keller Rohrback L.L.P. serves as lead and co-lead counsel in class action lawsuits throughout the country. With offices in New York, Seattle, Phoenix, Ronan, Oakland, and Santa Barbara, our Complex Litigation Group is proud to offer its expertise to clients nationwide. Our trial lawyers have obtained judgments and settlements on behalf of clients in excess of seven billion dollars.

Attorney Advertising. Prior results do not guarantee a similar outcome. Not licensed to practice law in all states. Please refer to our website for details.

Keller Rohrback L.L.P.Michael Meredith or Gretchen Freeman Cappio, Attorneys800-776-60441201 Third Avenue, Suite 3200Seattle, WA 98101consumer@kellerrohrback.comhttp://www.krcomplexlit.com

Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Mylan NV Charts.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Mylan NV Charts.